Hermien E K De Walle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3074577/publications.pdf

Version: 2024-02-01

66 papers

2,740 citations

28 h-index 50 g-index

69 all docs

69 docs citations

69 times ranked 3612 citing authors

#	Article	IF	Citations
1	Epidemiology of congenital diaphragmatic hernia in Europe: a register-based study. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2015, 100, F137-F144.	2.8	229
2	Long term trends in prevalence of neural tube defects in Europe: population based study. BMJ, The, 2015, 351, h5949.	6.0	180
3	Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. British Journal of Clinical Pharmacology, 2008, 65, 600-606.	2.4	151
4	Protective effect of periconceptional folic acid supplements on the risk of congenital heart defects: a registry-based case-control study in the northern Netherlands. European Heart Journal, 2010, 31, 464-471.	2.2	145
5	Prenatal diagnosis and prevalence of critical congenital heart defects: an international retrospective cohort study. BMJ Open, 2019, 9, e028139.	1.9	126
6	Estimating Global Burden of Disease due to congenital anomaly: an analysis of European data. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2018, 103, F22-F28.	2.8	122
7	Preventing neural tube defects in Europe: A missed opportunity. Reproductive Toxicology, 2005, 20, 393-402.	2.9	105
8	Accuracy of family history of cancer: clinical genetic implications. European Journal of Human Genetics, 2000, 8, 181-186.	2.8	91
9	Epidemiology of hypospadias in Europe: a registry-based study. World Journal of Urology, 2015, 33, 2159-2167.	2.2	88
10	Toward the effective surveillance of hypospadias Environmental Health Perspectives, 2004, 112, 398-402.	6.0	84
11	Genotype-phenotype correlations in L1 syndrome: a guide for genetic counselling and mutation analysis. Journal of Medical Genetics, 2010, 47, 169-175.	3.2	82
12	Hypospadias Prevalence and Trends in International Birth Defect Surveillance Systems, 1980–2010. European Urology, 2019, 76, 482-490.	1.9	74
13	Firstâ€trimester use of paroxetine and congenital heart defects: A populationâ€based caseâ€control study. Birth Defects Research Part A: Clinical and Molecular Teratology, 2010, 88, 94-100.	1.6	73
14	Use of asthma medication during pregnancy and risk of specific congenital anomalies: AÂEuropean case-malformed control study. Journal of Allergy and Clinical Immunology, 2015, 136, 1496-1502.e7.	2.9	67
15	A novel classification system to predict the pathogenic effects of CHD7 missense variants in CHARGE syndrome. Human Mutation, 2012, 33, 1251-1260.	2.5	65
16	Trisomy 13 and 18—Prevalence and mortality—A multiâ€registry population based analysis. American Journal of Medical Genetics, Part A, 2019, 179, 2382-2392.	1,2	59
17	Prevalence of microcephaly in Europe: population based study. BMJ, The, 2016, 354, i4721.	6.0	57
18	Ten years after the Dutch public health campaign on folic acid: the continuing challenge. European Journal of Clinical Pharmacology, 2008, 64, 539-543.	1.9	55

#	Article	IF	CITATIONS
19	Preferential Associations between Oral Clefts and Other Major Congenital Anomalies. Cleft Palate-Craniofacial Journal, 2008, 45, 525-532.	0.9	50
20	Maternal Recall of Prescription Medication Use During Pregnancy Using a Paper-Based Questionnaire. Drug Safety, 2013, 36, 43-54.	3.2	50
21	Periconceptional folic acid associated with an increased risk of oral clefts relative to non-folate related malformations in the Northern Netherlands: a population based case-control study. European Journal of Epidemiology, 2013, 28, 875-887.	5.7	41
22	P-Glycoprotein-Mediated Drug Interactions in Pregnancy and Changes in the Risk of Congenital Anomalies: A Case-Reference Study. Drug Safety, 2015, 38, 651-659.	3.2	39
23	Folic acid sensitive birth defects in association with intrauterine exposure to folic acid antagonists. Reproductive Toxicology, 2005, 20, 203-207.	2.9	33
24	Maternal high-dose folic acid during pregnancy and asthma medication in the offspring. Pharmacoepidemiology and Drug Safety, 2014, 23, 1059-1065.	1.9	32
25	Stillbirth and neonatal mortality in pregnancies complicated by major congenital anomalies: Findings from a large European cohort. Prenatal Diagnosis, 2017, 37, 1100-1111.	2.3	32
26	Clomiphene and hypospadias on a detailed level: Signal or chance?. Birth Defects Research Part A: Clinical and Molecular Teratology, 2006, 76, 249-252.	1.6	31
27	EUROlinkCAT protocol for a European population-based data linkage study investigating the survival, morbidity and education of children with congenital anomalies. BMJ Open, 2021, 11, e047859.	1.9	31
28	Spectrum of congenital anomalies among VACTERL cases: a EUROCAT population-based study. Pediatric Research, 2020, 87, 541-549.	2.3	30
29	Influence of educational level on determinants of folic acid use. Paediatric and Perinatal Epidemiology, 2003, 17, 256-263.	1.7	28
30	Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study. Pharmacoepidemiology and Drug Safety, 2010, 19, 808-813.	1.9	27
31	Actual Use of Medications Prescribed During Pregnancy: A Cross-Sectional Study Using Data from a Population-Based Congenital Anomaly Registry. Drug Safety, 2015, 38, 737-747.	3.2	27
32	Congenital clubfoot in Europe: A populationâ€based study. American Journal of Medical Genetics, Part A, 2019, 179, 595-601.	1.2	24
33	Disease-Modifying Antirheumatic Drugs in Pregnancy. Drug Safety, 2006, 29, 845-863.	3.2	23
34	Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins. Pharmacogenomics, 2014, 15, 1029-1041.	1.3	23
35	Analysis of Mortality among Neonates and Children with Spina Bifida: An International Registryâ€Based Study, 2001â€2012. Paediatric and Perinatal Epidemiology, 2019, 33, 436-448.	1.7	23
36	Prevention of Neural Tube Defects in Europe: A Public Health Failure. Frontiers in Pediatrics, 2021, 9, 647038.	1.9	23

#	Article	IF	CITATIONS
37	Prenatal diagnostic procedures used in pregnancies with congenital malformations in 14 regions of Europe. Prenatal Diagnosis, 2004, 24, 908-912.	2.3	19
38	Insulin analogues use in pregnancy among women with pregestational diabetes mellitus and risk of congenital anomaly: a retrospective population-based cohort study. BMJ Open, 2018, 8, e014972.	1.9	19
39	Maternal occupational exposure and oral clefts in offspring. Environmental Health, 2017, 16, 83.	4.0	18
40	Ten-Year Survival of Children With Congenital Anomalies: A European Cohort Study. Pediatrics, 2022, 149, .	2.1	18
41	Selection of controls in case-control studies on maternal medication use and risk of birth defects. Birth Defects Research Part A: Clinical and Molecular Teratology, 2007, 79, 652-656.	1.6	17
42	EUROmediCAT signal detection: an evaluation of selected congenital anomalyâ€medication associations. British Journal of Clinical Pharmacology, 2016, 82, 1094-1109.	2.4	17
43	Referral for genetic counseling after the birth of a child with a congenital anomaly in the Northern Netherlands. American Journal of Medical Genetics Part A, 2002, 112, 133-137.	2.4	16
44	Periconceptional folic acid use: Still room to improve. Birth Defects Research Part A: Clinical and Molecular Teratology, 2012, 94, 96-101.	1.6	16
45	Etiological diagnosis in limb reduction defects and the number of affected limbs: A populationâ€based study in the Northern Netherlands. American Journal of Medical Genetics, Part A, 2020, 182, 2909-2918.	1.2	15
46	A multiâ€country study of prevalence and early childhood mortality among children with omphalocele. Birth Defects Research, 2020, 112, 1787-1801.	1.5	14
47	Maternal risk factors for the <scp>VACTERL</scp> association: A <scp>EUROCAT</scp> case–control study. Birth Defects Research, 2020, 112, 688-698.	1.5	14
48	Prenatal diagnosis of urinary tract anomalies, a cohort study in the Northern Netherlands. Prenatal Diagnosis, 2018, 38, 130-134.	2.3	13
49	Multilevel analyses of related public health indicators: The European Surveillance of Congenital Anomalies (EUROCAT) Public Health Indicators. Paediatric and Perinatal Epidemiology, 2020, 34, 122-129.	1.7	13
50	Epidemiology of Pierreâ€Robin sequence in Europe: A populationâ€based EUROCAT study. Paediatric and Perinatal Epidemiology, 2021, 35, 530-539.	1.7	13
51	Knowledge and attitude regarding pharmacogenetics among formerly pregnant women in the Netherlands and their interest in pharmacogenetic research. BMC Pregnancy and Childbirth, 2017, 17, 120.	2.4	12
52	The impact of national prenatal screening on the time of diagnosis and outcome of pregnancies affected with common trisomies, a cohort study in the Northern Netherlands. BMC Pregnancy and Childbirth, 2017, 17, 4.	2.4	11
53	EUROmediCAT signal detection: a systematic method for identifying potential teratogenic medication. British Journal of Clinical Pharmacology, 2016, 82, 1110-1122.	2.4	10
54	Temporal and geographical variations in survival of children born with congenital anomalies in Europe: A multiâ€registry cohort study. Paediatric and Perinatal Epidemiology, 2022, 36, 792-803.	1.7	10

#	Article	IF	CITATIONS
55	The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descriptive study. Pharmacoepidemiology and Drug Safety, 2006, 15, 675-682.	1.9	8
56	Survival of children with rare structural congenital anomalies: a multi-registry cohort study. Orphanet Journal of Rare Diseases, 2022, 17, 142.	2.7	8
57	Methadone, Pierre Robin sequence and other congenital anomalies: case–control study. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2020, 105, 151-157.	2.8	7
58	Acardia: Epidemiologic findings and literature review from the International Clearinghouse for Birth Defects Surveillance and Research. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2011, 157, 262-273.	1.6	6
59	Maternal risk associated with the VACTERL association: A case–control study. Birth Defects Research, 2020, 112, 1495-1504.	1.5	5
60	Are congenital urinary tract and genital organ anomalies related to folic acid?. European Urology, 2016, 69, 544-546.	1.9	4
61	Maternal occupational exposure and congenital heart defects in offspring. Scandinavian Journal of Work, Environment and Health, 2020, 46, 599-608.	3.4	4
62	Reply to MartÃnez-FrÃas and RodrÃguez-Pinilla. Birth Defects Research Part A: Clinical and Molecular Teratology, 2008, 82, 175-175.	1.6	3
63	Use of hierarchical models to analyze European trends in congenital anomaly prevalence. Birth Defects Research Part A: Clinical and Molecular Teratology, 2016, 106, 480-488.	1.6	3
64	Maternal occupational exposure to solvents and gastroschisis in offspring - National Birth Defects Prevention Study 1997–2011. Occupational and Environmental Medicine, 2020, 77, 172-178.	2.8	3
65	Monitoring of risk factor/outcome combinations: a valuable supplement to birth defect monitoring. International Journal of Risk and Safety in Medicine, 1992, 3, 129-136.	0.6	2
66	Sex and congenital malformations: An international perspective. American Journal of Medical Genetics, Part A, 2005, 134A, 463-463.	1.2	1